Pyrazolone based TGFbetaR1 kinase inhibitors.
Guckian, K., Carter, M.B., Lin, E.Y., Choi, M., Sun, L., Boriack-Sjodin, P.A., Chuaqui, C., Lane, B., Cheung, K., Ling, L., Lee, W.C.(2010) Bioorg Med Chem Lett 20: 326-329
- PubMed: 19914068 
- DOI: 10.1016/j.bmcl.2009.10.108
- Primary Citation of Related Structures:  
3KCF - PubMed Abstract: 
Interruption of TGFbeta signaling through inhibition of the TGFbetaR1 kinase domain may prove to have beneficial effect in both fibrotic and oncological diseases. Herein we describe the SAR of a novel series of TGFbetaR1 kinase inhibitors containing a py ...